Abstract: Provided is a nonwoven fabric for skin care products. The nonwoven fabric includes: a thermoplastic resin fiber having a single fiber diameter of 50 nm or more and 800 nm or less; and a cellulose fiber. A tensile strength of the cellulose fiber measured in accordance with JIS L 1015:2010 8.7.2 is 1.9 cN/dtex or less, a total content of the thermoplastic resin fiber and the cellulose fiber is 85% by mass or more relative to a total mass of the nonwoven fabric for skin care products, a content ratio by mass of the thermoplastic resin fiber and the cellulose fiber (thermoplastic resin fiber/cellulose fiber) is 0.23 to 1.50, and a density of the nonwoven fabric for skin care products is 0.08 g/cm3 to 0.16 g/cm3.

Abstract: A lip balm formulation for applying to a lip including at least one lipid, a surfactant, and a nicotine active, wherein the lip balm formulation includes about 25 wt. % to 60 wt. % of the surfactant based on the total weight of the formulation; wherein the surfactant includes a mixture of mono- and diglycerides and propylene glycol; wherein the surfactant has an HLB of 4; wherein the lip balm formulation includes about 30 wt. % to 60 wt. % of the at least one lipid based on the total weight of the formulation; wherein the at least one lipid includes hydrogenated palm oil; and wherein the surfactant minimizes the surface tension of the at least one lipid.

Abstract: The invention relates to a solid cosmetic composition comprising anhydrous spheroids dispersed in a solid aqueous continuous phase. The invention is also directed toward a process for preparing a solid cosmetic composition according to the invention, and also a process for making up and/or caring for bodily and/or facial skin using a solid cosmetic composition according to the invention. The invention is also directed toward a stick or a solid gel cast in a dish or a pot, and more particularly a lipstick, a foundation, and an antisun stick, comprising a cosmetic composition according to the invention.

Abstract: Water-in-oil sunscreen emulsion compositions including an aqueous phase emulsified within an external fatty phase are provided. The external fatty phase includes at least one silicone fatty compound and at least about 10% by weight of organic UV filters with respect to the entire sunscreen composition. The compositions include an emulsifying silicone elastomer and a non-elastomeric silicone surfactant. The compositions further include swellable clay and pigment.

Abstract: Described herein are personal care compositions comprising a complex comprising a plurality of short chain fatty acids; along with methods of making and using same.

Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a foam boosting surfactant, a foam boosting copolymer, a foam stabilizer, and a chelating agent. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4?-trichloro-2?hydroxy-diphenylether), have rapid cidal activity, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.

Abstract: Zinc di-(dibutyryl lysinate) s, topical compositions comprising the same, and their use in skin lightening/brightening/even toning applications.

Abstract: Several embodiments disclosed herein relate to formulations having antimicrobial and/or sanitizing effects, and uses of the same. In particular, the formulations and methods of using same provide, in several embodiments, an immediate and a persistent antimicrobial effect against a broad spectrum of microorganisms.

Abstract: Disclosed are polymers, methods of making polymers, and compositions, focused on cross-linking heterocycles comprising a moiety of Formula I with thiols and thiolates.

Abstract: The present invention is directed to a cosmetic composition comprising: (a) one or more esters of sucrose and fatty acids, wherein the fatty acids are selected from those having from about 12 to about 24 carbon atoms, and wherein the sucrose esters are selected from the group consisting of mono-ester, di-ester, tri-ester, tetra-ester, and mixtures thereof; and (b) one or more solvents selected from those having Hildebrand Solubility Parameter of from about 23 to about 31.5 (J/cm3)1/2 and Polar component of Hansen Solubility Parameter of from about 4.5 to about 10.5 (J/cm3)1/2. The cosmetic compositions of the present invention dissolve the sucrose esters in the cosmetic compositions, even when the sucrose esters are contained at higher levels in the compositions and/or even when the sucrose esters are contained in an aqueous phase of the cosmetic composition.

Abstract: The use of the compound or a pharmaceutically acceptable salt thereof in the preparation of an external preparation for skin whitening is provided, and the compound is shown in formula (I-1): The present disclosure can enhance the whitening activity of salidroside while taking full advantage of the protective effect of salidroside sugar ring, where the phenol residues of salidroside are restructured to obtain salidroside-plus (SP-037), which is 1-(3,5-dihydroxyphenyl)ethyl-?-D-glucoside and/or a salt thereof. The whitening effect of the compound is tested through a series of experiments.

Abstract: The present disclosure relates to novel cell penetrating peptides and their applications in cosmetic compositions. These compositions include cell penetrating botulinum toxin recombinant proteins, which are fusion proteins of the cell-penetrating peptides and botulinum toxin. Also disclosed are polynucleotides encoding these recombinant proteins and recombinant expression vectors comprising these polynucleotides. The cell penetrating botulinum toxin recombinant proteins serve as active ingredients in the cosmetic compositions.

Abstract: The present invention relates to a use of a peptide containing an amino acid sequence represented by SEQ ID NO: 1 derived from the Rv2626c protein of Mycobacterium tuberculosis for treating sepsis. The peptide is excellent in inhibiting the inflammatory response induced by macrophages and is excellent in inhibiting the increase in the number of bacterial colonies, and thus can be usefully used for the treatment of sepsis.

Abstract: The present invention relates to a topical composition that can be used to treat skin laxity, cellulite and to firm, smooth and/or tone skin.

Abstract: A body milk for improved skin moisture level comprises hyaluronic acid and/or salts thereof. PEG-40 Sorbitan Perisostearate and Polyglyceryl-3 Diisostearate and Tocopherol, and one or more lipids selected from isopropyl palmitate, isododecane, almond oil, the preparation being free of BHT.

Abstract: A composition for coating keratin fibres, in the form of a wax-in-water emulsion including, in a first continuous aqueous phase, at least one legume starch having an amylose content greater than or equal to 30%, at least one plasticiser chosen among the polyols, at least one wax, at least one emulsifier and at least one colouring agent. Also, the use of such a composition in order to provide keratin fibres, in particular eyelashes, with a lengthening and curling effect.

Abstract: The present invention relates to a personal washing composition comprising a detersive surfactant, at least one rheology modifying polymer, at least one cationic conditioning polymer, at least one benefit agent, and an anionic polymer of polysulfonic acid. The composition is a sulfate-free or substantial sulfate-free personal washing composition. The present invention further relates to a method of achieving improved conditioning benefits and/or improved deposition of benefit agents onto hair and/or skin.

Abstract: Compositions and methods for reshaping keratin-rich substrates while forming adherent flexible films contain emulsified or soluble mixtures of silanols and hemiaminals or the reaction products of silanols and hemiaminals including silylated hemiaminals. A method for treating split-ends in hair is also described.

Abstract: A biological self-assembled nanocrystal injection having a lymphatic targeting function and an administration method for targeting a lymphatic system using the biological self-assembled nanocrystal injection. The injection comprises 0.05-5% of mitoxantrone and a salt thereof, 0.1-10% of an osmotic pressure regulator, 0.001-0.1% of a buffering agent, 0.01-0.1% of an antioxidant, 0.05-1% of an adsorbent, and 0-20% of a filler. The administration method is interstitial injection, and a lymph node will produce a blue color visible to the naked eye after passive targeting to the lymphatic system.

Abstract: Disclosed herein are biocompatible materials useful for tissue regeneration and repair, wherein the bioactive polymer may be in the form of a hydrogel, for example a thermoresponsive hydrogel. This bioactive polymer and a resulting hydrogel, may be used for the regeneration of bone tissue. Accordingly, also disclosed herein are methods of treating a bone defect in a mammal, the methods comprising administering a therapeutically effective amount of a hydrogel formed by the bioactive polymer to the mammal to treat the bone defect.

Abstract: The present disclosure relates to parenteral nutritional formulations, including ready-to-use parenteral nutrition formulations. More particularly, the present disclosure is directed to lipid formulations or emulsions and multi-chamber containers comprising same, wherein the lipid emulsion contains glycerophosphorylcholine as a choline source. The present disclosure further relates to methods of providing choline to a patient in need of parenteral nutrition and methods of avoiding and/or treating choline deficiency and liver damage.

Abstract: A topical copper ion treatment in basic form composes a copper ion-containing solution composed of a biocompatible solution containing copper ions obtained by leaching of the copper ions from copper metal into the solution. The copper ion-containing solution can be combined with various carriers to form various forms of the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. A method of making the copper ion-containing solution involves placing solid copper metal in a quantity of a biocompatible solution and maintaining the solution at a specified temperature for a predetermined period of time during which copper ions each from the copper metal into the solution, and thereafter separating the solution from the solid copper metal.

Abstract: Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

Abstract: Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Abstract: The present invention relates to a method to load a water insoluble phospholipid as nanoparticles to load into a hydrogel contact lens in autoclaving process during the hydrogel contact lens manufacturing process without an extra manufacturing step and without swelling the hydrogel contact lens with an organic solvent. The phospholipid nanoparticles loaded in hydrogel contact lens subsequently releases to the eye upon wearing.

Abstract: The present invention relates to a method to load a water insoluble phospholipid as nanoparticles to load into a hydrogel contact lens in autoclaving process during the hydrogel contact lens manufacturing process without an extra manufacturing step and without swelling the hydrogel contact lens with an organic solvent. The phospholipid nanoparticles loaded in hydrogel contact lens subsequently releases to the eye upon wearing.

Abstract: Products configured for oral use and methods for preparing such products are provided. In some embodiments, oral products described herein may comprise at least one active ingredient in an amount of 10 weight percent or less, a sugar alcohol, and a gum, such that the product is in the form of a pastille. In some embodiments, oral products described herein may include at least one active ingredient in an amount of about 10 weight percent or less, a sugar substitute, and a sugar alcohol syrup, such that the product is in the form of a lozenge.

Abstract: The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein the dosage form and the bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Abstract: In one aspect, the disclosure relates to compositions for the extended release of drugs in the retina. In a further aspect, the present disclosure provides methods of preparing extended release compositions comprising a therapeutic agent for use in retinal drug delivery. In various other aspects, the present disclosure provides methods for delivery of the disclosed compositions comprising a therapeutic agent to the retina via intravitreal injection. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Provided in the present disclosure are a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic agent or prophylactic agent.

Abstract: This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.

Abstract: An object of the present invention is to provide a novel formulation containing sucroferric oxyhydroxide, particularly a novel formulation that can be ingested without being chewed. The present invention relates to a novel formulation discovered based on the finding that a granule containing sucroferric oxyhydroxide that has a specific size and shape and also has specific physicochemical properties can be easily ingested without being chewed, and has formulation properties suitable for industrial manufacturing as a result of intensive studies to provide a novel formulation containing sucroferric oxyhydroxide.

Abstract: Articles and methods for delivering a therapeutic agent to a subject are described. These articles and methods may be useful, in some cases, for the delivery of therapeutic agents to the colon of a subject. In some embodiments, an article is configured to release a secretion inducing agent e.g., to stimulate the release of intestinal fluids. The article, in some embodiments, comprises a therapeutic agent such that the stimulated release of intestinal fluid increases the amount of therapeutic agent available for absorption by the colon. For example, in some embodiments, the articles and methods described herein advantageously promote increased absorption of therapeutic agents in subjects as compared to traditionally administered therapeutic agents without additional components such as a secretion inducing agent. In some embodiments, articles and methods described herein may increase the motility of the colon of a subject.

Abstract: A metformin tablet, a metformin tablet for relieving pain and reducing inflammation, and a manufacturing method thereof. The tablet for relieving pain and reducing inflammation comprises: a filler, a diluent, an excipient, a binder, a slow-release agent, a sweetener, and a medicinal powder; the excipient comprises: at least one of PVP, PEG, and polymer; the medicinal powder comprises: at least one of metformin and the excipient. The metformin tablet comprises: a hollow part, a thick colloidal layer formed on an outer side of the hollow part, and a powder colloidal layer formed on an outer side of the thick colloidal layer. The tablet for relieving pain and reducing inflammation comprises: a thick colloidal layer, a powder colloidal layer formed on an outer side of the thick colloidal layer, and a hollow part located at a center of the tablet and on an inner side of the thick colloidal layer.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: The present invention provides for a method of treatment of IgA nephropathy, which method comprises: (i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711>/Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test; (a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.

Abstract: The present invention provides for a method of treatment of IgA nephropathy, which method comprises: (i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711>/Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test; (a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.

Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

Abstract: One of the significant challenges to translation of intravenously administered nanomaterials has been complement-mediated infusion reactions which can be lethal. Slow infusions can reduce infusion reactions, but slow infusions are not always possible in applications like controlling bleeding following trauma. Nanocapsules based on polyurethane are introduced as candidates that do not substantially activate complement protein C5a and the PEGylation and functionalization of the nanocapsules with the GRGDS peptide to create a new class of hemostatic nanomaterials is disclosed. Advantageously, the nanocapsules substantially avoid complement-mediated infusion reactions, promote faster clotting than controls, maintain maximum clot firmness, and do not activate pro-inflammatory cytokines.

Abstract: The present invention relates to: a photothermal agent which includes a mussel adhesive protein; and photothermal-responsive nanoparticles that generate a biocompatible gas by means of light and heat and release a drug. Nanoparticles according to the present invention exhibit a photothermal effect when near-infrared rays are applied thereto, and may be applied to trimodality therapy in which a biocompatible gas is generated by means of light and heat to induce the release of a drug.

Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.

Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.

Abstract: A short wave ultraviolet light machine is configured to disrupt microbes. The machine has a housing having an outer shell and a hollow inner portion. A solar panel is joined to the outer shell and electrically coupled to a battery charge controller within the hollow inner portion. A lithium polymer energy storage device is arranged within the hollow inner portion and is electrically coupled to the battery charge controller. A short-wave ultraviolet light emitting diode module is arranged on the outer shell and electrically coupled to the battery charge controller with an electronic controller module. A proximity sensor module is arranged on the outer shell and electrically coupled to the electronic controller module. The proximity sensor detects a surface and engages the short-wave ultraviolet light emitting diode module to emit a short wave ultraviolet light that disrupts microbes proximate the short wave ultraviolet light emitting diode machine.

Abstract: The present invention provides device designed to provide sheets that are disposable and water resistant. The present invention includes a plurality of chairs with numbers, a container, sheets having numbers that match one or more of the plurality of numbers attached to the chairs, a chair transceiver and a container transceiver.

Abstract: A sterilization tunnel has an inlet opening for pharmaceutical containers to be sterilised, an outlet opening, a high-temperature sterilisation chamber and a cooling chamber in line therewith and communicating with the outlet opening. A conveyor means transports the containers through the sterilisation chamber and the cooling chamber up to the outlet opening. A transfer plane is positionable in a first configuration aligned with the conveyor to transfer the containers out of the tunnel through the outlet opening. A shutter opens and closes the outlet opening. The transfer plane is movable and positionable in a second configuration inside the cooling chamber and misaligned with respect to the conveyor. When the transfer plane is inside the cooling chamber, the shutter is lowerable in abutment with a seal element.

Abstract: An antimicrobial lighting system is used to reduce microbial growth on surfaces in or on air conditioning and/or heating equipment. In some examples, antimicrobial light within one or more antimicrobial wavelength ranges is applied to inactivate one or more microorganisms on target surface(s) within or on a packaged terminal air conditioner (PTAC). The antimicrobial light may include light within a first antimicrobial wavelength range and/or light within a second antimicrobial wavelength range. The antimicrobial lighting system may include an array of individually controllable antimicrobial light segments. An array controller may individually control activation of the one or more antimicrobial light segments based on the status information or commands received from a PTAC controller or from an external computing device.

Abstract: An apparatus, system, and method for decontamination.

Abstract: A lighting array including one or more antimicrobial light segments, each light segments including one or more antimicrobial light sources, is configured to emit light sufficient to inactivate one or more microorganisms on a touch screen display surface. The lighting array may individually control activation of the one or more antimicrobial light segments based on user presence information, time of day information, and/or touch screen display usage information. A touch screen display assembly includes a housing, a touch screen display and a lighting array including one or more antimicrobial light segments.

Abstract: Disclosed is a portable sterilization and disinfection apparatus for sterilizing and disinfecting a space, wherein the portable sterilization and disinfection apparatus may enable ultrafine spray and accurate oriented spray, may expand a spraying distance, and may be freely moved to any space so as to effectively sterilize and disinfect the space.